Pfizer have announced positive Phase III clinical trial results for their JAK inhibitor, Xeljanz (tofacitinib).
The results from data taken from two Phase III clinical trials provide additional support for the drug’s use to treat moderate to severe psoriasis.
Pfizer commented that the results from the trials show that both tofacitinib 10mg and 5mg tablets twice daily were superior to placebo in achieving a Physician’s Global Assessment response of “clear” or “almost clear”, in addition to at least a 75% reduction in Psoriasis Area and Severity Index (PASI75).
Pfizer yesterday announced that they have agreed to purchase two of Baxter International’s commercially marketed vaccines and part of Baxter’s production facilities for $635 million.
The purchase will give Pfizer access to Baxter’s meningitis C jab NeisVac-C and FSME-IMMUN/TicoVac, a vaccine that helps protect against tick-borne encephalitis – an infection of the brain transmitted by the bite of ticks infected with the TBE-virus.
Pfizer yesterday announced positive results from their phase III clinical trial comparing prophylaxis regimen of BeneFIX Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly, with on-demand treatment for moderately severe to severe hemophilia B.
Top-line results showed that the clinical trial met its primary endpoint, with a statistically noteworthy reduction in the annualised bleeding rate in comparison to on-demand treatment of the drug.
Pfizer have announced positive late-stage clinical data from a phase III trial of Xalkori, in comparison to chemotherapy.
Pfizer revealed that the clinical study met the primary objective of significantly prolonging progression-free survival in previously-untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-squamous non-small cell lung cancer (NSCLC), when compared to standard platinum-based chemotherapy regimens.
Pfizer announced yesterday that Chantix/Champix (varenicline) has been shown to help smokers unable to quit ‘cold turkey’ kick their habit by slowly reducing the amount of cigarettes they smoke.
The initial clinical study to assess the drug demonstrated that Chantix/Champix helped improve abstinence rates, in people wanting to reduce smoking prior to quitting.
Four Scottish health boards have partnered up with Pfizer to become the organisation’s second INSPIRE site within the UK, aimed at driving clinical research.
The four health boards are NHS Grampian, Greater Glasgow & Clyde, Lothian and Tayside.
The health boards have already heavily invested in the research endeavour through NHS Research Scotland (NRS), a collaboration involving Scottish NHS Boards and the Scottish government’s Chief Scientist Office.
It is looking unlikely that Pfizer’s Bosulif (also known as Bosutinib) will be made available on the NHS, after cost regulator, NICE, released preliminary draft guidance rejecting the drug’s use in patients with chronic myeloid leukaemia (CML).
Bosulif has already been approved in Europe as well as the US for use after treatment with one or more tyrosine kinase inhibitor, i.e. Novartis’ Gleevec and Tasigna or Bristol-Myers Squibb’s Sprycel.
Pfizer is believed to be cutting approximately 600 jobs this month from their primary care business.
The organisation’s primary care sector have a variety of key drugs, including pain killer Lyrica, ED drug Viagra and arthritis drug Celebrex.
Pfizer are celebrating today after US regulators approved their rheumatoid arthritis drug, Xeljanz, yesterday. The treatment is the first Janus kinase (JAK) inhibitor to be approved for rheumatoid arthritis.
The US Food and Drug Administration (FDA) have given the green light to Xeljanz (tofacitinib) 5mg twice-daily for the medication of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
The Scottish Medicines Consortium (SMC) has authorised the use of Pfizer’s Xiapex (collagenase clostridium histolyticum) on the NHS for patients with Dupuytren’s contracture, reversing their earlier decision to reject the drug.
Xiapex is the first medication available for the condition, which previously was only treatable with surgery, meaning that the SMC’s endorsement good news for patients who are entitled to receive it.